Empagliflozin benefits in patients with heart failure and preserved ejection fraction

被引：0
|
作者：
Anker, Stefan D. [1 ,2 ,3 ]
Butler, Javed
Usman, Muhammad Shariq
Filippatos, Gerasimos
Ferreira, Joao Pedro
Bocchi, Edimar
Boehm, Michael
Brunner-La Rocca, Hans Pieter
Choi, Dong-Ju
Chopra, Vijay
Chuquiure, Eduardo
Giannetti, Nadia
Esteban Gomez-Mesa, Juan
Janssens, Stefan
Januzzi, James L.
Gonzalez-Juanatey, Jose R.
Merkely, Bela
Nicholls, Stephen J.
Perrone, Sergio V.
Pina, Ileana L.
Ponikowski, Piotr
Senni, Michele
Sim, David
Spinar, Jindrich
Squire, Iain
Taddei, Stefano
Tsutsui, Hiroyuki
Verma, Subodh
Vinereanu, Dragos
Zhang, Jian
Iwata, Tomoko
Schnee, Janet M.
Brueckmann, Martina
Pocock, Stuart J.
Zannad, Faiez
机构：
[1] Charite Univ Med Berlin, Dept Cardiol CVK, German Ctr Cardiovasc Res DZHK Partner Site Berli, Berlin, Germany
[2] Charite Univ Med Berlin, Berlin Inst Hlth Ctr Regenerat Therapies BCRT, German Ctr Cardiovasc Res DZHK Partner Site Berli, Berlin, Germany
[3] Wroclaw Med Univ, Inst Heart Dis, Wroclaw, Poland
来源：
NATURE MEDICINE | 2022年 / 28卷 / 12期
关键词：
D O I：
10.1038/s41591-022-02050-4
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Subgroup analysis of the EMPEROR-Preserved clinical trial of the glucose-lowering drug empagliflozin in chronic heart failure with left ventricular ejection fraction (LVEF) >40% found improved clinical outcomes in the cohort of patients with LVEF >= 50%. This is, to our knowledge, the first time a drug therapy has been unequivocally demonstrated to benefit this patient population.
引用
收藏
页码：2480 / 2481
页数：2
相关论文
共 50 条
  • [1] Empagliflozin benefits in patients with heart failure and preserved ejection fraction
    [J]. Nature Medicine, 2022, 28 : 2480 - 2481
  • [2] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
    不详
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21):
  • [3] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao P.
    Bocchi, Edimar
    Boehm, Michael
    Brunner-La Rocca, Hans-Peter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure-Valenzuela, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Carson, Peter
    Lam, Carolyn Su Ping
    Marx, Nikolaus
    Zeller, Cordula
    Sattar, Naveed
    Jamal, Waheed
    Schnaidt, Sven
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16): : 1451 - 1461
  • [4] Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction
    Pooni, Rajan S.
    Ismail, Tevfik F.
    [J]. CLINICAL MEDICINE, 2022, 22 (01) : 75 - 76
  • [5] Empagliflozin in the treatment of heart failure with preserved ejection fraction
    Morbach, C.
    Frantz, S.
    Nitschmann, S.
    [J]. INNERE MEDIZIN, 2022, 63 (07): : 808 - 809
  • [6] Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
    Zhou, Jennifer
    Liew, Danny
    Kaye, David M.
    Zoungas, Sophia
    Stub, Dion
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2022, 15 (10): : E008638
  • [7] What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin?
    Monzo, Luca
    Ferrari, Ilaria
    Cicogna, Francesco
    Tota, Claudia
    Calo, Leonardo
    [J]. JOURNAL OF CARDIOVASCULAR MEDICINE, 2022, 23 (08) : 567 - 569
  • [8] Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
    Ferreira, Joao Pedro
    Butler, Javed
    Zannad, Faiez
    Filippatos, Gerasimos
    Schueler, Elke
    Steubl, Dominik
    Zeller, Cordula
    Januzzi, James L.
    Pocock, Stuart
    Packer, Milton
    Anker, Stefan D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (12) : 1129 - 1137
  • [9] Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
    Zheng, Jimmy
    Parizo, Justin T.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    [J]. JAMA INTERNAL MEDICINE, 2022, 182 (12) : 1278 - 1288
  • [10] A Dose Comparison Study of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
    Macdonald, Blair J.
    Turgeon, Ricky D.
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2024, 40 (03) : 388 - 388
12345